Brain+ (BRAINP) Investor Update summary

Product Launch, Roadmap, and Solution Overview

• Launch of CST Assistant as a medical device in the U.K. is imminent, with a full product roadmap for 2025 and extensions to 2026, including advanced home-based therapy and remote monitoring.

• The platform, known as Aila/Ayla, includes CST Assistant, Home Companion, Virtual CST Assistant, and CST Planner, covering the patient journey from pre-diagnosis to ongoing care.

• Designed for scalability, cost-effectiveness, and integration with health system records, the solution standardizes and expands access to CST.

• Offers 150+ validated CST sessions, adaptable content, and supports both in-person and virtual delivery.

• UK usability studies confirm product-market fit, value, and cost benefit.

Market Opportunity and Challenges

• Dementia is the second leading cause of death globally, with 139 million projected cases by 2050 and global health expenditure reaching €9.1 trillion.

• Diagnosis can take up to a year, and only 31% of diagnosed patients are referred for CST.

• Barriers include long waitlists, lack of standardization, and resource shortages, limiting CST access and scalability.

Clinical Validation and Impact

• CST is the world's leading non-drug dementia therapy, recommended by NICE and adopted in 39 countries, with strong clinical evidence and no side effects.

• Clinical benefits include a 6-month delay in cognitive decline, improved communication, quality of life, and social interaction.

• The platform is co-developed with global CST experts and praised for usability and impact by clinicians and users.